

Notice of Allowability	Application No. 10/589,099	Applicant(s) CHOI ET AL.
	Examiner SUSANNA MOORE	Art Unit 1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 12/3/10.

2. The allowed claim(s) is/are 1-7 and 13.

3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some* c) None of the:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.

(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
1) hereto or 2) to Paper No./Mail Date _____.

(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of
Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)

5. Notice of Informal Patent Application

2. Notice of Draftsperson's Patent Drawing Review (PTO-948)

6. Interview Summary (PTO-413),
Paper No./Mail Date 1/27/11, 2/3/11.

3. Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____.

7. Examiner's Amendment/Comment

4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material

8. Examiner's Statement of Reasons for Allowance

9. Other _____.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Scott Reid on February 3, 2011.

In claim 1, the phrase "arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl" has been replaced with "aryl, heteroaryl, cycloalkyl or heterocycloalkyl" on page 3, lines 11-12.

In claim 1, the terms "C₁₋₆alkenyl, C₁₋₆alkynyl" has been replaced with "C₂₋₆alkenyl, C₂₋₆alkynyl" on page 4, line 2.

In claim 2, the phrase "arylalkyl and heteroarylalkyl" has been replaced with "aryl and heteroaryl" on page 4, lines 5.

In claim 2, the terms "C₁₋₆alkenyl," has been replaced with "C₂₋₆alkenyl," on page 4, line 2.

In claims 4 and 6, the terms "2-(methyl- amino-carbamoyl)-ethyl, 2-(ethyl-amino-carbamoyl)-ethyl," have been removed from page 5, lines 12-13 and page 7, line 4, respectively.

In claims 4 and 6, the terms "4-amino-cyclohexyl-formamidyl, 4-amino-cyclohexyl-formamidyl-methyl," have been removed from page 6, lines 9-10 and page 7, lines 16-17, respectively.

In claims 4 and 6, the term “2-(dimethylamino-ethylcarbamoyl)-ethyl,” has been replaced with “N-(2-(dimethylamino)ethyl)-3-phenylpropanamide” on page 5, lines 10-11 and page 7, line 2, respectively.

In claim 13, a period has been placed at the end of the table on page 28.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached on M-F 8:00-5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Susanna Moore/
Examiner, Art Unit 1624

Application/Control Number: 10/589,099

Art Unit: 1624

Page 4